Press releaseGlobe Newswire
NervGen Pharma
NGEN · TSX
$1.43+$0.01 (+0.70%)TodayMarket closed ·
Prev close $1.42
About NGEN
- Employees
- 7
- Headquarters
- Vancouver, British Columbia
- Listed
- Mar 13, 2019
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Website
- nervgen.com
NGEN key statistics
- Market cap
- 226.72M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 462.42K
- Volume
- 944.03K
- Open price
- $1.41
- High today
- $1.44
- Low today
- $1.38
- 52 Week high
- $6.30
- 52 Week low
- $1.42
NervGen Pharma (NGEN) at a glance
As of Oct 23, 2026, NervGen Pharma (NGEN) shares are priced at $1.43, giving the company a market cap of 226.72M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $1.38 and $1.44. The current price is 3.6% above the day's low and 0.8% below its high.
Volume so far is 944.03K shares, above the average of 462.42K shares a day.
Over the past year NervGen Pharma has ranged from $1.42 to $6.30, and now sits 0% of the way up that range.
NervGen Pharma met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY25 it reported -$0.06 per share against an estimate of -$0.0606.
The average analyst price target is $5.70, 298.5% above the current price, from 2 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
100%of 2 analyst ratings say Buy
- Buy100.0%
- Hold0.0%
- Sell0.0%
Price target · 6 analystsAvg $5.70
- Low
- $3.71
- Now
- $1.43
- High
- $7.49
NGEN earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 5 of the last 8 quarters, by 23.8% on average.
- Q4 FY22: reported -$0.10 per share against an estimate of -$0.1212
- Q1 FY24: reported -$0.04 per share against an estimate of -$0.0707
- Q2 FY24: reported -$0.11 per share against an estimate of -$0.0909
- Q3 FY24: reported -$0.07 per share against an estimate of -$0.0909
- Q4 FY24: reported -$0.13 per share against an estimate of -$0.0859
- Q1 FY25: reported -$0.06 per share against an estimate of -$0.0909
- Q2 FY25: reported -$0.13 per share against an estimate of -$0.0505
- Q3 FY25: reported -$0.06 per share against an estimate of -$0.0606
NGEN news
- Press releaseGlobe Newswire
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
- Press releaseGlobe Newswire
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
- Avi Kapoor
Crude Oil Edges Higher; US Consumer Sentiment Falls In May
- Avi Kapoor
Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results
- Press releaseGlobe Newswire
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
12 Health Care Stocks Moving In Thursday's After-Market Session
Similar companies
Companies in the same industry as NervGen Pharma
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.